erectile%20dysfunction
ERECTILE DYSFUNCTION

Erectile dysfunction is the inability to attain and maintain an erection enough to have satisfactory sexual performance for ≥3 months.

It is when the patient complains of partial erection that could not attain vaginal penetration.

Complete loss of penile rigidity is uncommon.

Initial penile erections can penetrate but early detumescence occurs without ejaculation.

Prevention

Treat Psychosocial Factors

  • Confronting depression or substance abuse
  • Sexual education/correction of misinformation

Discontinue Offending Medications

  • Many common medications may affect male sexual function
    • Eg antidepressants, antipsychotics, anti-arrhythmics, many antihypertensives, anti-androgens & steroids

Counselling

Sexual Counseling & Education

  • Encompass sex therapy, psychosocial therapy & marital therapy
  • May be appropriate for patient &/or partner
  • May be used to address & correct relationship issues, stress factors (eg work, finances, family, etc)
  • Decreased sexual drive may be due to psychologic issues & individual may benefit from sexual therapy
  • Use as adjunct to other erectile dysfunction therapy to address patient’s psychological reaction to their need for erectile dysfunction treatment
  • Sexual counseling & education may be preferred by patients/partners because it is noninvasive & has broad applicability

Follow Up

  • Patients receiving phosphodiesterase inhibitors must have regular follow-up of efficacy, side effects & any relevant change in their health status (especially cardiovascular health) including medications
  • Failure to respond to phosphodiesterase inhibitor may be due to: 
    • Hormonal abnormalities
    • Drug interactions
    • Food interference w/ absorption
    • Timing & frequency of dosing
    • Lack of adequate sexual stimulation
    • Heavy alcohol use
    • Patient’s relationship w/ his partner
  • A patient who fails initial trial of phosphodiesterase inhibitor (after above factors are modified) may be given a different phosphodiesterase inhibitor or proceed w/ other more invasive therapies for erectile dysfunction
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.